Kim Kim

Dr. Kim Kim


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
JLJieun Lee
Jieun Lee
HPHye Soo Park
Hye Soo Park
HJHee jin Jung
Hee jin Jung
YPYu Jung Park
Yu Jung Park
MKMin Kyung Kang
Min Kyung Kang
HMHyung Ryong Moon
Hyung Ryong Moon
Ten 2-mercaptobenzimidazole (2-MBI) analogs were synthesized as potential tyrosinase inhibitors because mercapto-containing compounds can bind to copper ions at the active site of tyrosinase to inhibit enzyme activity. Nine 2-MBI analogs showed sub-micromolar IC50 values for mushroom tyrosinase monophenolase activity; analog 4 was 280-fold more potent than kojic acid, and in diphenolase activity, 6 was 970-fold more potent than kojic acid. The inhibition mode of the 2-MBI analogs was investigated using kinetic studies supported by docking simulations. Benzimidazoles without the 2-mercapto substituent of the 2-MBI analogs lost their tyrosinase inhibitory activity, implying that the 2-mercapto substituent plays an important role in tyrosinase inhibition. The 2-MBI analogs exerted potent antioxidant effects against 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS), 2,2-diphenyl-1-picrylhydrazyl (DPPH), and reactive oxygen species (ROS). The results obtained from apple slices and human embryonic kidney cells (HEK-293) suggest that most 2-MBI analogs are sufficiently safe candidates to delay the browning of apple slices effectively. Thus, these results support the potential use of 2-MBI analogs as anti-browning agents in foods such as mushrooms, vegetables, and fruits.

13 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
HJHee jin Jung
Hee jin Jung
KKKim Kim
Kim Kim
HPHyeon Seo Park
Hyeon Seo Park
HPHye Soo Park
Hye Soo Park
JKJeongin Ko
Jeongin Ko
HMHyung Ryong Moon
Hyung Ryong Moon
Fifteen compounds (1–15) constructed on a hybrid structure combining a β-phenyl-α,β-unsaturated carbonyl template and a 2-aminothiazol-4(5H)-one scaffold were designed and synthesized as potential novel anti-tyrosinase substances. Two compounds (10 and 15) showed more potent inhibition against mushroom tyrosinase than kojic acid, and the inhibitory activity of 10 (IC50 value: 1.60 μM) was 11 times stronger than that of kojic acid. Lineweaver–Burk plots indicated that these two compounds were competitive inhibitors that bound to the mushroom tyrosinase active site, which was supported by in silico experiments. Compound 10 was an anti-tyrosinase and anti-melanogenic substance in B16F10 cells and was more potent than kojic acid, without cytotoxicity. Compound 15 exhibited the most potent effect on zebrafish larval depigmentation and showed a depigmentation effect comparable to kojic acid, even at a concentration 200 times lower. Compounds 8 and 10 exhibited strong antioxidant capacities, scavenging 2,2-diphenyl-1-picrylhydrazyl, (2,2-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid)+ radicals, and reactive oxygen species. Hybrid compounds 10 and 15 are potential therapeutic agents for skin hyperpigmentation disorders.

26 December 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
HJHee jin Jung
Hee jin Jung
HPHyeon Seo Park
Hyeon Seo Park
YJYeonsoo Jeong
Yeonsoo Jeong
GKGa Young Kim
Ga Young Kim
HLHyunju Lee
Hyunju Lee
HMHyung Ryong Moon
Hyung Ryong Moon
N-Benzylthiocarbamate (NBTC) analogs 1–10 were synthesized as potential Cu2+-chelating tyrosinase inhibitors. Most analogs exhibited strong Cu2+-chelating activity, but none inhibited mushroom tyrosinase (mTYR) activity better than kojic acid (KA). However, owing to their potent cellular TYR inhibitory activity, all analogs, except 8, inhibited melanin formation in B16F10 cells more than KA. Analogs 3, 4, and 9 exhibited stronger antimelanogenic properties than N-phenylthiourea. The TYR inhibitory activity of the analogs of mTYR and B16F10 TYR was probably different because mTYR and mammalian TYR have different structural characteristics. All analogs had a potency to significantly scavenge reactive oxygen species (ROS). Analog 1 was very effective in reducing browning in potato juice. Furthermore, analog 3 inhibited zebrafish larval pigmentation 2000 times more potently than KA and was more effective than N-phenylthiourea. It is believed that their capacity to scavenge ROS amplifies their antimelanogenic effects. Exogenously added CuSO4 attenuated the inhibitions of cellular TYR activity and melanin formation in B16F10 cells caused by analog 9. This result might have been due to the externally added Cu2+ ions forming chelates with 9. The differential TYR inhibitory activity of NBTC analogs appeared to be due to their high sensitivity to interactions with TYRs of different origins.

16 October 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
HJHee jin Jung
Hee jin Jung
HPHyeon Seo Park
Hyeon Seo Park
KKKim Kim
Kim Kim
HPHye Soo Park
Hye Soo Park
YPYujin Park
Yujin Park
HMHyung Ryong Moon
Hyung Ryong Moon
2-Mercaptomethylbenzo[d]imidazole (2-MMBI) derivatives were designed and synthesized as tyrosinase (TYR) chelators using 2-mercaptomethylimidazole scaffolds. Seven of the ten 2-MMBI derivatives exhibited stronger inhibition of mushroom TYR activity than kojic acid. Their ability to chelate copper ions was demonstrated through experiments using the copper chelator pyrocatechol violet and assays measuring TYR activity in the presence or absence of exogenous CuSO4. The inhibition mechanisms of derivatives 1, 3, 8, and 9, which showed excellent TYR inhibitory activity, were elucidated through kinetic studies and supported by the docking simulation results. Derivatives 3, 7, 8, and 10 significantly inhibited cellular TYR activity and melanin production in B16F10 cells in a dose-dependent manner, with stronger potency than kojic acid. Furthermore, in situ, derivatives 7 and 10 showed stronger inhibitory effects on B16F10 cell TYR activity than kojic acid. Six derivatives, including 8, showed highly potent depigmentation in zebrafish larvae, outpacing kojic acid even at 200–670 times lower concentrations. Additionally, all derivatives could scavenge for reactive oxygen species without causing cytotoxicity in epidermal cells. These results suggested that 2-MMBI derivatives are promising anti-melanogenic agents.

18 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
KKKim Kim
Kim Kim
HJHee jin Jung
Hee jin Jung
YKYoung Eun Kim
Young Eun Kim
DJDaeun Jeong
Daeun Jeong
HPHyeon Seo Park
Hyeon Seo Park
HMHyung Ryong Moon
Hyung Ryong Moon
Based on the fact that substances with a β-phenyl-α,β-unsaturated carbonyl (PUSC) motif confer strong tyrosinase inhibitory activity, benzylidene-3-methyl-2-thioxothiazolidin-4-one (BMTTZD) analogs 1–8 were prepared as potential tyrosinase inhibitors. Four analogs (1–3 and 5) inhibited mushroom tyrosinase strongly. Especially, analog 3 showed an inhibitory effect that was 220 and 22 times more powerful than kojic acid in the presence of l-tyrosine and l-dopa, respectively. A kinetic study utilizing mushroom tyrosinase showed that analogs 1 and 3 competitively inhibited tyrosinase, whereas analogs 2 and 5 inhibited tyrosinase in a mixed manner. A docking simulation study indicated that analogs 2 and 5 could bind to both the tyrosinase active and allosteric sites with high binding affinities. In cell-based experiments using B16F10 cells, analogs 1, 3, and 5 effectively inhibited melanin production; their anti-melanogenic effects were attributed to their ability to inhibit intracellular tyrosinase activity. Moreover, analogs 1, 3, and 5 inhibited in situ B16F10 cellular tyrosinase activity. In three antioxidant experiments, analogs 2 and 3 exhibited strong antioxidant efficacy, similar to that of the positive controls. These results suggest that the BMTTZD analogs are promising tyrosinase inhibitors for the treatment of hyperpigmentation-related disorders.

23 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
HPHyeon Seo Park
Hyeon Seo Park
HJHee jin Jung
Hee jin Jung
HPHye Soo Park
Hye Soo Park
KKKim Kim
Kim Kim
YPYujin Park
Yujin Park
HMHyung Ryong Moon
Hyung Ryong Moon
To discover novel anti-melanogenic compounds with tyrosinase inhibitory activity, (Z)-3-benzyl-5-benzylidene-2-thioxothiazolidin-4-one ((Z)-BBTT) analogs 1–12, designed based on the hybrid structure of a β-phenyl-α,β-unsaturated carbonyl motif and a 3-benzyl-2-thioxothiazolidin-4-one scaffold, were synthesized as novel tyrosinase inhibitors. Of the 12 analogs, 2 (6 and 8) showed mushroom tyrosinase inhibitory activity similar to that of kojic acid, a representative tyrosinase inhibitor, and 3 analogs (1–3) exhibited mushroom tyrosinase inhibitory activity that was more potent than that of kojic acid. In particular, analog 3 revealed highly potent inhibition with an IC50 value of 90 nM, which was 214 times lower than that of kojic acid (IC50 value = 19.22 μM). A kinetic study using mushroom tyrosinase and analogs 1–3 and 6 demonstrated that these analogs were competitive inhibitors, which was further supported by in silico studies. Analogs 1 and 3 have strong anti-melanogenic potency in B16F10 mammalian cells owing to their anti-tyrosinase activity without perceptible cytotoxicity in melanoma cells (B16F10) and the main epidermal cells (HaCaT). Moreover, analog 3 exhibited strong antioxidant capacity, scavenging reactive oxygen species, 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) cation radical, and 2,2-diphenyl-1-picrylhydrazyl radical, partially contributing to its anti-melanogenic effect. (Z)-BBTT analogs, including analog 3, may be promising candidates for inhibiting melanin production.